(Q43011642)

12 November 2017

title

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy (English)

1 reference

12 November 2017

1 reference

Young-Woong Won

4

0 references

author name string

Seung Tae Kim

1

1 reference

12 November 2017

Jeeyun Lee

2

1 reference

12 November 2017

Jeong-Hoon Kim

3

1 reference

12 November 2017

Jong-Mu Sun

5

1 reference

12 November 2017

Jina Yun

6

1 reference

12 November 2017

Yeon Hee Park

7

1 reference

12 November 2017

Jin Seok Ahn

8

1 reference

12 November 2017

Keunchil Park

9

1 reference

12 November 2017

Myung-Ju Ahn

10

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

12 November 2017

1 reference

12 November 2017

volume

116

1 reference

12 November 2017

issue

12

1 reference

12 November 2017

page(s)

3025-3033

1 reference

12 November 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Treatment of metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Treatment principles in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25130

7 January 2021

Identifiers

DOI

10.1002/CNCR.25130

1 reference

release_etqqtyha2bbdfl7emnpay6ocky

12 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/etqqtyha2bbdfl7emnpay6ocky

24 November 2022

mapped directly with Wikidata item

1 reference